ClinicalTrials.gg
CompletedNCT05166109Updated Sep 15, 2026Results posted

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

A Phase 2 interventional study of Vamorolone and Placebo in Becker Muscular Dystrophy, sponsored by ReveraGen BioPharma, Inc.. Completed at 2 sites in 2 countries. Open to male participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by ReveraGen BioPharma, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
62nd of 171
46 · median 25
Started
2022
with 14 others
Phase 2
57 of 232
4 open now
Registered
176th of 232
by date

Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 62nd largest by enrollment of the 171 interventional ones that give a count, is one of 15 that started in 2022, is one of 57 in phase 2, and was the 176th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 64 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

This Phase II pilot study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, PD, and exploratory clinical efficacy of vamorolone 500mg (250mg for body weight \<50 kg) daily administered orally compared to placebo over a treatment period of 24 weeks in males with BMD.

Funding Source - FDA OOPD

Read the detailed description

This Phase II pilot study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, PD, and exploratory clinical efficacy of vamorolone 500mg (250mg for body weight \<50 kg) daily administered orally compared to placebo over a treatment period of 24 weeks in males with BMD.

The study is comprised of a Pretreatment Screening Period of up to 5 weeks duration (unless extended to accommodate varicella vaccination), a 1-day Pretreatment Baseline Period, a 24-week Treatment Period, and a 4-week Dose-tapering Period (for subjects not continuing directly with further vamorolone treatment). Subjects will be enrolled into this study at the time written informed consent is given, and administered study medication only after completion of all Pretreatment Screening assessments to confirm eligibility.

Subjects will be assessed for safety, tolerability, PK, PD, and effect on physical functioning at scheduled visits throughout the study. Screening assessments will be performed prior to baseline assessments on Day -1 and first administration of study medication on Day 1.

After completion of Screening and Baseline assessments, subjects will return to the study clinic on Day 1 for safety, PK and PD assessments prior to administration of the first dose of study medication. Additional on-site study visits will occur at Week 4, Week 12, and Week 24. Adverse events, including serious adverse events (SAEs), and concomitant medications will be recorded throughout the study. A Data and Safety Monitoring Board (DSMB) will review SAEs and other pertinent safety data at regular intervals during the study, and make recommendations to the Sponsor and Study Team regarding study conduct.

Subject diaries will be dispensed at the Day 1, Week 12, and Week 24 (for subjects participating in the Dose-tapering Period) Visits to record AEs, changes to concomitant medications taken during the study, and any missed or incomplete doses of study medication.

The scheduled Week 12 and Week 24 assessments may be performed over a 2-day period, if necessary, to facilitate scheduling.

Subjects who complete the VBP15-BMD-001 study assessments through the Week 24 Visit may be given the opportunity to continue to receive vamorolone as part of an expanded access or compassionate use program.

Subjects who complete the VBP15-BMD-001 study and will enroll directly into an expanded access or compassionate use program to continue vamorolone treatment will be discharged from the VBP15-BMD-001 study following completion of all Week 24 assessments. Subjects who will not continue vamorolone treatment in the expanded access or compassionate use program will have their study medication dose tapered during a 4-week Dose-tapering Period to taper study medication prior to discharge from the study. For these subjects, site study staff will contact the subject or parent(s)/guardian(s) by telephone at Week 26 to ensure that the dose tapering is proceeding according to protocol, to assess potential signs or symptoms of adrenal suppression, and to address any questions the subject or parent(s)/guardian(s) may have.

In the event that any clinical or laboratory parameters remain abnormal at the time of discharge from the study, the subject will be followed medically, as clinically indicated.

Any subject who discontinues the study prior to the Week 24 Visit should return to the study unit for scheduled Week 24 assessments at the time of early withdrawal and a Week 28 Visit following the taper, whenever possible, assuming the subject has not withdrawn consent. Any subject who withdraws early from the study after study medication dosing has begun should undergo dose-tapering following early completion of the Week 24 assessments and a Week 28 Visit following the taper.

03

Conditions studied

  • Becker Muscular Dystrophy

Keywords

  • Becker Muscular Dystrophy
  • Duchenne Muscular Dystrophy
  • Duchenne and Becker Muscular Dystrophy
  • Muscular Dystrophy
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject or Subject's parent(s) or legal guardian (s) has (have) provided written and Health Insurance Portability and Accountability Act (HIPAA) authorization, where applicable, prior to any study-related procedures;
  2. Subject is a male and has a confirmed diagnosis of Becker dystrophy as defined as:

    1. Identifiable mutation within the DMD gene (deletion/duplication of one or more exons), where reading frame can be predicted as 'in-frame', and clinical picture consistent with Becker dystrophy, OR
    2. Complete dystrophin gene sequencing showing an alteration (small mutation, duplication, other) that is expected to allow production of an internally deleted dystrophin protein, with a typical clinical picture of Becker dystrophy;
  3. Subject is ≥ 18 years of age and \<65 years of age at time of informed consent;
  4. Subject is able to perform the timed run/walk 10 meters assessment (TTRW) in ≤ 30 sec at screening; assistive devices, cane or walker, are allowed.
  5. Subject has an NSAA score ≤ 32 at screening.
  6. Clinical laboratory test results are within the normal range at the Screening Visit, or if abnormal, are not , in the opinion of the Investigator. (Note: Serum gamma glutamyl transferase [GGT], creatinine, and total all must be ≤ at the Screening Visit). While and ALT can be elevated due to disease of muscle or liver, the study PI will review any increases of AST or ALT. If above upper limit of normal (ULN), then study PI will assess whether the increases are likely of muscle origin to determine inclusion.
  7. Subject has not received oral or other oral agents for at least 3 months prior to first administration of study medication. [Note: Inhaled and/or topical glucocorticoids are permitted if last use is at least 4 weeks prior to first administration of study medication or if administered at stable dose beginning at least 4 weeks prior to first administration of study medication and anticipated to be used at the stable dose regimen for the duration of the study];
  8. Subject has evidence of chicken pox immunity as determined by:

    1. Presence of IgG antibodies to varicella, as documented by a positive test result from the local laboratory from blood collected during the Screening Period; OR
    2. Documentation, provided at the Screening Visit, that the subject has received 2 doses of varicella vaccine, with or without serologic evidence of immunity, with the second of the 2 immunizations given at least 14 days prior to first administration of study medication;
  9. Subject is willing and able to comply with scheduled visits, study medication administration plan, and study procedures.
  10. Subject agrees to use barrier methods during his participation in this study and for 30 days after the tapering dose is completed.

Exclusion criteria

Exclusion Criteria:

  1. Subject has current or history of major renal or hepatic impairment, uncontrolled diabetes mellitus (defined as a diagnosis of diabetes with random glucose more than 1.5x at screening and the patient has symptoms of polyuria or polydipsia) or ;
  2. Subject has current or history of chronic systemic fungal or viral infections;
  3. Subject has had an acute illness within 4 weeks prior to the first dose of study medication
  4. Subject has used mineralocorticoid receptor agents, such as spironolactone, eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium), or mexrenone (mexrenoate potassium) within 4 weeks prior to administration of study medication;
  5. Subject has evidence of symptomatic cardiomyopathy [Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary unless cardiac is less than 40%];
  6. Subject has an allergy or to the study medication or to any of its constituents;
  7. Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the Investigator;
  8. Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator;
  9. Subject is taking (or has taken within 4 weeks prior to first dose of study medication) herbal remedies and supplements which can impact muscle strength and function (e.g., Co-enzyme Q10, creatine, etc);
  10. Subject has been administered a within 14 days prior to the first dose of study medication;
  11. Subject is currently taking any other drug or has taken any other investigational drug within 3 months prior to first dose of study medication; or
  12. Subject has previously been enrolled in the VBP15-BMD-001 study or any other vamorolone study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Vamorolone 500mg/day [250mg if <50kg body weight]

    Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).

    Drug: Vamorolone

  • Placebo comparator
    Placebo

    Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).

    Drug: Placebo

Interventions

  • Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.

    Also known as: VBP15

  • DrugPlacebo

    Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.

    Also known as: Placebo to vamorolone

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 5.0

    Clinical AEs and clinical laboratory AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 Dose-limiting toxicities will be defined as follows: 1. The presence of a CTCAE Grade ≥ 3 AE, considered to be probably or definitely related to study drug 2. The presence of a CTCAE Grade ≥ 3 clinical laboratory AE considered to be probably or definitely related to study drug 3. Deterioration of the muscle condition, unexpected for the natural course of BMD and without other clear cause

    Time frame: 24 weeks

  2. Total Number of Adverse Events as Assessed by CTCAE Version 5.0

    Clinical AEs and clinical laboratory AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 Dose-limiting toxicities will be defined as follows: 1. The presence of a CTCAE Grade ≥ 3 AE, considered to be probably or definitely related to study drug 2. The presence of a CTCAE Grade ≥ 3 clinical laboratory AE considered to be probably or definitely related to study drug 3. Deterioration of the muscle condition, unexpected for the natural course of BMD and without other clear cause

    Time frame: 24 weeks

Secondary outcomes

  1. Pharmacokinetics as Measured by Cmax

    Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis

    Time frame: Day 1

  2. Pharmacokinetics as Measured by Tmax

    Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis

    Time frame: Day 1

  3. Pharmacokinetics as Measured by Dose-normalized Cmax

    Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis

    Time frame: Day 1

  4. Safety as Measured by Serum Concentration of Osteocalcin

    Change from baseline to Week 24 will be assessed for each treatment group.

    Time frame: Week 24

  5. Safety as Measured by Serum Concentration of Hemoglobin A1c (HbA1c)

    Change from baseline to Week 24 will be assessed for each treatment group.

    Time frame: Week 24

  6. Safety as Measured by Fasting Serum Concentration of Glucose

    Change from baseline to week 24 for each treatment group.

    Time frame: Week 24

  7. Safety as Measured by Fasting Serum Concentration of Insulin

    Change from baseline to week 24 for each treatment group.

    Time frame: Week 24

  8. Safety as Measured by Concentration of Salivary Cortisol

    First-in-morning salivary cortisol levels will be measured. Cortisol measures falling below 3.6 µg/dL (or 100 nM) will be considered to be indicative of the development of adrenal suppression. Cortisol will be assessed for each treatment group.

    Time frame: Week 24

  9. Efficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (CD23)

    CD23 (also known as Fc epsilon RII) concentration at Week 24.

    Time frame: Week 24

  10. Efficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (MDC)

    MDC (macrophage-derived chemokine) concentration at Week 24.

    Time frame: Week 24

  11. Efficacy as Measured by Time to Run/Walk Velocity (TTRWV)

    Change from baseline to week 24 for each treatment group.

    Time frame: Week 24

  12. Efficacy as Measured by North Star Ambulatory Assessment (NSAA) Score

    North Star Ambulatory Assessment (NSAA). The assessment's score can range from 0 to 34. Higher scores indicate a better outcome assessing functional mobility. Data is presented as change from baseline to week 24 for each treatment group.

    Time frame: Week 24

07

Results

Posted Sep 15, 2026
Limitations and caveats
This was a pilot study with a small sample size that was adequate for initial safety characterization. There was not an available Becker dystrophy data set to determine sample size for efficacy. The study duration may have been too short for a slowly progressive disorder such as Becker dystrophy, particularly in adults.

Participant flow

Participant flow — Overall Study
MilestoneVamorolonePlacebo
Started2613
Completed2613
Not completed00

Outcome measures

PrimaryNumber of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 5.0

Clinical AEs and clinical laboratory AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 Dose-limiting toxicities will be defined as follows: 1. The presence of a CTCAE Grade ≥ 3 AE, considered to be probably or definitely related to study drug 2. The presence of a CTCAE Grade ≥ 3 clinical laboratory AE considered to be probably or definitely related to study drug 3. Deterioration of the muscle condition, unexpected for the natural course of BMD and without other clear cause

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 5.0
ParticipantsVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 5.01710
SecondaryPharmacokinetics as Measured by Cmax

Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis

Time frame:
Day 1
Reported as:
Geometric mean · ng/ml
Pharmacokinetics as Measured by Cmax
ng/mlVamorolone (250mg)Vamorolone (500mg)
Pharmacokinetics as Measured by Cmax860 ± 01045.70 ± 53.5
SecondaryPharmacokinetics as Measured by Tmax

Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis

Time frame:
Day 1
Reported as:
Median · hours
Pharmacokinetics as Measured by Tmax
hoursVamorolone (250mg)Vamorolone (500mg)
Pharmacokinetics as Measured by Tmax2.95 ± 02.07 (0.97 to 3.02)
SecondaryPharmacokinetics as Measured by Dose-normalized Cmax

Blood will be collected from all subjects at the Day 1 Visit, at 1, 2 and 3 hours post-dose, for vamorolone PK analysis

Time frame:
Day 1
Reported as:
Geometric mean · ng/ml/mg
Pharmacokinetics as Measured by Dose-normalized Cmax
ng/ml/mgVamorolone (250mg)Vamorolone (500mg)
Pharmacokinetics as Measured by Dose-normalized Cmax1.7 ± 02.1 ± 53.5
SecondarySafety as Measured by Serum Concentration of Osteocalcin

Change from baseline to Week 24 will be assessed for each treatment group.

Time frame:
Week 24
Reported as:
Mean · ng/ml
Safety as Measured by Serum Concentration of Osteocalcin
ng/mlVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Safety as Measured by Serum Concentration of Osteocalcin-0.54 ± 5.502-0.98 ± 3.505
SecondarySafety as Measured by Serum Concentration of Hemoglobin A1c (HbA1c)

Change from baseline to Week 24 will be assessed for each treatment group.

Time frame:
Week 24
Reported as:
Mean · % NGSP
Safety as Measured by Serum Concentration of Hemoglobin A1c (HbA1c)
% NGSPVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Safety as Measured by Serum Concentration of Hemoglobin A1c (HbA1c)0.13 ± 0.272-0.02 ± 0.259
SecondarySafety as Measured by Fasting Serum Concentration of Glucose

Change from baseline to week 24 for each treatment group.

Time frame:
Week 24
Reported as:
Mean · mg/ml
Safety as Measured by Fasting Serum Concentration of Glucose
mg/mlVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Safety as Measured by Fasting Serum Concentration of Glucose-10.911 ± 8.8944-2.284 ± 5.9165
SecondarySafety as Measured by Fasting Serum Concentration of Insulin

Change from baseline to week 24 for each treatment group.

Time frame:
Week 24
Reported as:
Mean · mU/L
Safety as Measured by Fasting Serum Concentration of Insulin
mU/LVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Safety as Measured by Fasting Serum Concentration of Insulin2.11 ± 9.962-3.63 ± 17.092
SecondarySafety as Measured by Concentration of Salivary Cortisol

First-in-morning salivary cortisol levels will be measured. Cortisol measures falling below 3.6 µg/dL (or 100 nM) will be considered to be indicative of the development of adrenal suppression. Cortisol will be assessed for each treatment group.

Time frame:
Week 24
Reported as:
Mean · nmol/L
Safety as Measured by Concentration of Salivary Cortisol
nmol/LVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Safety as Measured by Concentration of Salivary Cortisol1.17 ± 0.918.80 ± 6.18
SecondaryEfficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (CD23)

CD23 (also known as Fc epsilon RII) concentration at Week 24.

Time frame:
Week 24
Reported as:
Mean · pg/ml
Efficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (CD23)
pg/mlVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Efficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (CD23)2507.17 ± 960.232566.27 ± 805.15
SecondaryEfficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (MDC)

MDC (macrophage-derived chemokine) concentration at Week 24.

Time frame:
Week 24
Reported as:
Mean · pg/ml
Efficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (MDC)
pg/mlVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Efficacy as Measured by Concentration of Serum Pharmacodynamic Biomarkers (MDC)447.11 ± 112.01562.99 ± 179.04
PrimaryTotal Number of Adverse Events as Assessed by CTCAE Version 5.0

Clinical AEs and clinical laboratory AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 Dose-limiting toxicities will be defined as follows: 1. The presence of a CTCAE Grade ≥ 3 AE, considered to be probably or definitely related to study drug 2. The presence of a CTCAE Grade ≥ 3 clinical laboratory AE considered to be probably or definitely related to study drug 3. Deterioration of the muscle condition, unexpected for the natural course of BMD and without other clear cause

Time frame:
24 weeks
Reported as:
Number · Events
Total Number of Adverse Events as Assessed by CTCAE Version 5.0
EventsVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Total Number of Adverse Events as Assessed by CTCAE Version 5.04325
SecondaryEfficacy as Measured by Time to Run/Walk Velocity (TTRWV)

Change from baseline to week 24 for each treatment group.

Time frame:
Week 24
Reported as:
Mean · meters/second
Efficacy as Measured by Time to Run/Walk Velocity (TTRWV)
meters/secondVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Efficacy as Measured by Time to Run/Walk Velocity (TTRWV)-0.05 ± 0.272-0.05 ± 0.164
SecondaryEfficacy as Measured by North Star Ambulatory Assessment (NSAA) Score

North Star Ambulatory Assessment (NSAA). The assessment's score can range from 0 to 34. Higher scores indicate a better outcome assessing functional mobility. Data is presented as change from baseline to week 24 for each treatment group.

Time frame:
Week 24
Reported as:
Mean · Units on a scale
Efficacy as Measured by North Star Ambulatory Assessment (NSAA) Score
Units on a scaleVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Efficacy as Measured by North Star Ambulatory Assessment (NSAA) Score0.16 ± 1.5990.00 ± 1.706

Adverse events

Collected over From enrollment until end of follow-up, up to 28 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vamorolone 500mg/Day [250mg if <50kg Body Weight]0/26 (0%)1/26 (3.8%)13/26 (50%)
Placebo0/13 (0%)0/13 (0%)10/13 (76.9%)
Most frequent serious events
Most frequent serious events
EventVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
Gastroesophageal reflux diseaseGastrointestinal disorders1/260/13
Most frequent other events
Showing 10 of 16
Most frequent other events
EventVamorolone 500mg/Day [250mg if <50kg Body Weight]Placebo
FallInjury, poisoning and procedural complications2/265/13
Upper respiratory tract infectionInfections and infestations1/262/13
Back painMusculoskeletal and connective tissue disorders2/260/13
COVID-19Infections and infestations1/261/13
Foot fractureInjury, poisoning and procedural complications1/261/13
HypertriglyceridemiaMetabolism and nutrition disorders2/260/13
Muscular weaknessMusculoskeletal and connective tissue disorders2/260/13
MyalgiaMusculoskeletal and connective tissue disorders1/261/13
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/261/13
RashSkin and subcutaneous tissue disorders1/261/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)VamorolonePlaceboTotal
<=18 years000
Between 18 and 65 years261339
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)VamorolonePlaceboTotal
Female000
Male261339
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VamorolonePlaceboTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American202
White231134
More than one race011
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VamorolonePlaceboTotal
Hispanic or Latino011
Not Hispanic or Latino261238
Unknown or Not Reported000
08

Study locations

2 sites
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15261, United States
  • Azienda Ospedale Universita Padova
    Padova, 35129, Italy
09

References and documents

Publications

  • Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, McDonald CM, Kuntz NL, Finkel RS, Guglieri M, Bushby K, Tulinius M, Nevo Y, Ryan MM, Webster R, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Siener C, Jaros M, Shale P, McCall JM, Nagaraju K, van den Anker J, Conklin LS, Cnaan A, Gordish-Dressman H, Damsker JM, Clemens PR; Cooperative International Neuromuscular Research Group. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. 2019 Sep 24;93(13):e1312-e1323. doi: 10.1212/WNL.0000000000008168. Epub 2019 Aug 26. PubMed 31451516 ↗
  • Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, Guglieri M, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, Kerchner L, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, Gordish-Dressman H, Hagerty L, Dang UJ, Damsker JM, Schwartz BD, Mengle-Gaw LJ, McDonald CM; CINRG VBP15 and DNHS Investigators. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020 Sep 21;17(9):e1003222. doi: 10.1371/journal.pmed.1003222. eCollection 2020 Sep. PubMed 32956407 ↗
  • Heier CR, Yu Q, Fiorillo AA, Tully CB, Tucker A, Mazala DA, Uaesoontrachoon K, Srinivassane S, Damsker JM, Hoffman EP, Nagaraju K, Spurney CF. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance. 2019 Feb 11;2(1):e201800186. doi: 10.26508/lsa.201800186. Print 2019 Feb. PubMed 30745312 ↗
  • Mavroudis PD, van den Anker J, Conklin LS, Damsker JM, Hoffman EP, Nagaraju K, Clemens PR, Jusko WJ. Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy. J Clin Pharmacol. 2019 Jul;59(7):979-988. doi: 10.1002/jcph.1388. Epub 2019 Feb 11. PubMed 30742306 ↗
  • Damsker JM, Cornish MR, Kanneboyina P, Kanneboyina I, Yu Q, Lipson R, Phadke A, Knoblach SM, Panchapakesan K, Morales M, Fiorillo AA, Partridge T, Nagaraju K. Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset. Inflamm Res. 2019 Nov;68(11):969-980. doi: 10.1007/s00011-019-01279-z. Epub 2019 Aug 24. PubMed 31446438 ↗
  • Akkad H, Cacciani N, Llano-Diez M, Corpeno Kalamgi R, Tchkonia T, Kirkland JL, Larsson L. Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model. Acta Physiol (Oxf). 2019 Feb;225(2):e13172. doi: 10.1111/apha.13172. Epub 2018 Sep 6. PubMed 30120816 ↗
  • Li X, Conklin LS, van den Anker J, Hoffman EP, Clemens PR, Jusko WJ. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. J Clin Pharmacol. 2020 Oct;60(10):1385-1396. doi: 10.1002/jcph.1632. Epub 2020 May 20. PubMed 32434278 ↗
  • Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, Nagaraju K, Gordish-Dressman H, Damsker JM, McCall JM. Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids. 2018 Jun;134:43-52. doi: 10.1016/j.steroids.2018.02.010. Epub 2018 Mar 8. PubMed 29524454 ↗
  • Almeida LEF, Damsker JM, Albani S, Afsar N, Kamimura S, Pratt D, Kleiner DE, Quezado M, Gordish-Dressman H, Quezado ZMN. The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice. Sci Rep. 2018 Apr 17;8(1):6081. doi: 10.1038/s41598-018-24274-6. PubMed 29666400 ↗
  • Wells E, Kambhampati M, Damsker JM, Gordish-Dressman H, Yadavilli S, Becher OJ, Gittens J, Stampar M, Packer RJ, Nazarian J. Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor. Oncotarget. 2017 Feb 7;8(6):9366-9374. doi: 10.18632/oncotarget.14070. PubMed 28030841 ↗
  • Liu X, Wang Y, Gutierrez JS, Damsker JM, Nagaraju K, Hoffman EP, Ortlund EA. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24285-24293. doi: 10.1073/pnas.2006890117. Epub 2020 Sep 11. PubMed 32917814 ↗
  • Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res. 2018 Oct;136:140-150. doi: 10.1016/j.phrs.2018.09.007. Epub 2018 Sep 13. PubMed 30219580 ↗
  • Fiorillo AA, Tully CB, Damsker JM, Nagaraju K, Hoffman EP, Heier CR. Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone. Physiol Genomics. 2018 Sep 1;50(9):735-745. doi: 10.1152/physiolgenomics.00134.2017. Epub 2018 Jun 8. PubMed 29883261 ↗
  • Sreetama SC, Chandra G, Van der Meulen JH, Ahmad MM, Suzuki P, Bhuvanendran S, Nagaraju K, Hoffman EP, Jaiswal JK. Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit. Mol Ther. 2018 Sep 5;26(9):2231-2242. doi: 10.1016/j.ymthe.2018.07.021. Epub 2018 Aug 27. PubMed 30166241 ↗
  • Dang UJ, Ziemba M, Clemens PR, Hathout Y, Conklin LS; CINRG Vamorolone 002/003 Investigators; Hoffman EP. Serum biomarkers associated with baseline clinical severity in young steroid-naive Duchenne muscular dystrophy boys. Hum Mol Genet. 2020 Aug 29;29(15):2481-2495. doi: 10.1093/hmg/ddaa132. PubMed 32592467 ↗
  • Ziemba M, Barkhouse M, Uaesoontrachoon K, Giri M, Hathout Y, Dang UJ, Gordish-Dressman H, Nagaraju K, Hoffman EP. Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice. PLoS One. 2021 Feb 22;16(2):e0246507. doi: 10.1371/journal.pone.0246507. eCollection 2021. PubMed 33617542 ↗
  • Dadgar S, Wang Z, Johnston H, Kesari A, Nagaraju K, Chen YW, Hill DA, Partridge TA, Giri M, Freishtat RJ, Nazarian J, Xuan J, Wang Y, Hoffman EP. Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. J Cell Biol. 2014 Oct 13;207(1):139-58. doi: 10.1083/jcb.201402079. PubMed 25313409 ↗
  • Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, Sali A, Miller BK, Phadke A, Scheffer L, Quinn J, Tatem K, Jordan S, Dadgar S, Rodriguez OC, Albanese C, Calhoun M, Gordish-Dressman H, Jaiswal JK, Connor EM, McCall JM, Hoffman EP, Reeves EK, Nagaraju K. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med. 2013 Oct;5(10):1569-85. doi: 10.1002/emmm.201302621. Epub 2013 Sep 9. PubMed 24014378 ↗
  • Damsker JM, Dillingham BC, Rose MC, Balsley MA, Heier CR, Watson AM, Stemmy EJ, Jurjus RA, Huynh T, Tatem K, Uaesoontrachoon K, Berry DM, Benton AS, Freishtat RJ, Hoffman EP, McCall JM, Gordish-Dressman H, Constant SL, Reeves EK, Nagaraju K. VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice. PLoS One. 2013 May 7;8(5):e63871. doi: 10.1371/journal.pone.0063871. Print 2013. PubMed 23667681 ↗
  • Freishtat RJ, Nino G, Tsegaye Y, Alcala SE, Benton AS, Watson AM, Reeves EK, Haider SK, Damsker JM. Pharmacologically-induced mitotic synchrony in airway epithelial cells as a mechanism of action of anti-inflammatory drugs. Respir Res. 2015 Oct 29;16:132. doi: 10.1186/s12931-015-0293-4. PubMed 26511361 ↗
  • Dillingham BC, Knoblach SM, Many GM, Harmon BT, Mullen AM, Heier CR, Bello L, McCall JM, Hoffman EP, Connor EM, Nagaraju K, Reeves EKM, Damsker JM. VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. Cell Mol Neurobiol. 2015 Apr;35(3):377-387. doi: 10.1007/s10571-014-0133-y. Epub 2014 Nov 13. PubMed 25392236 ↗
  • Garvin LM, Chen Y, Damsker JM, Rose MC. A novel dissociative steroid VBP15 reduces MUC5AC gene expression in airway epithelial cells but lacks the GRE mediated transcriptional properties of dexamethasone. Pulm Pharmacol Ther. 2016 Jun;38:17-26. doi: 10.1016/j.pupt.2016.04.004. Epub 2016 Apr 29. PubMed 27133900 ↗
  • Damsker JM, Conklin LS, Sadri S, Dillingham BC, Panchapakesan K, Heier CR, McCall JM, Sandler AD. VBP15, a novel dissociative steroid compound, reduces NFkappaB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis. Inflamm Res. 2016 Sep;65(9):737-43. doi: 10.1007/s00011-016-0956-8. Epub 2016 Jun 3. PubMed 27261270 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Aug 2025, 37 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 37 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2021
First posted
Dec 21, 2021
StartActual
Jul 7, 2022
Primary completionActual
Aug 18, 2025
CompletionActual
Aug 18, 2025
Results first posted
Sep 15, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05166109
Lead sponsor
ReveraGen BioPharma, Inc.
Responsible party
Sponsor
First posted
Dec 21, 2021
Start date
Jul 7, 2022
Primary completion
Aug 18, 2025
Completion
Aug 18, 2025
Results posted
Sep 15, 2026
Last update
Sep 15, 2026

Study contacts

Paula Clemens, M.D.
study chair · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vamorolone

Start the discussion